SCIg vs IVIG: Comparing Subcutaneous and Intravenous Immunoglobulin Therapy

“Can I do this at home instead?” It is one of the first questions patients ask after months of hospital or clinic visits for intravenous immunoglobulin (IVIG). Subcutaneous immunoglobulin (SCIg) makes that possible for many people — but the switch involves more than just a change of scenery. Route, dosing, side effects, and insurance all factor into a decision that affects daily life for years.

The Basics: Two Routes, Same Antibodies

Both IVIG and SCIg deliver pooled human immunoglobulin G (IgG) from thousands of donors. The antibodies are identical in function. What differs is how they enter the body:

• IVIG goes directly into a vein through an IV line, delivering a large dose all at once, typically every 3-4 weeks.
• SCIg is infused into the fatty tissue just under the skin, delivering smaller doses more frequently — usually weekly, though some products allow monthly dosing.

This seemingly simple distinction creates cascading differences in how treatment feels, where it happens, and how the body responds.

Head-to-Head Comparison Table

The Bioavailability Factor

One of the most important — and least discussed — aspects of switching from IVIG to SCIg is the bioavailability adjustment. When immunoglobulin is infused subcutaneously, it absorbs more slowly through the lymphatic system rather than entering the bloodstream directly. As a result, the SCIg dose typically needs to be approximately 137% of the equivalent IVIG dose to achieve the same serum IgG levels.

In practical terms, if a patient receives 30 grams of IVIG monthly, the equivalent SCIg dose would be approximately 41 grams per month, divided across weekly infusions (roughly 10 grams per week). This higher gram amount does not mean more side effects — the body absorbs it gradually, which actually produces a gentler physiological response.

Side Effects: Systemic vs Local

The side effect profiles of IVIG and SCIg differ fundamentally because of the delivery route.

IVIG Side Effects

Because a large volume enters the bloodstream rapidly, IVIG side effects tend to be systemic: headaches (sometimes severe), chills, fever, nausea, fatigue, and muscle aches. More serious but less common risks include aseptic meningitis, blood clots, and kidney injury — particularly with rapid infusion rates or in patients with risk factors.

SCIg Side Effects

SCIg side effects are predominantly local: redness, swelling, itching, or mild pain at the injection site. These reactions are common during the first few weeks of therapy but typically diminish substantially within 2-3 months. Systemic reactions are rare with subcutaneous delivery because the immunoglobulin enters the circulation gradually.

Lifestyle and Independence

For many patients, the lifestyle differences matter as much as the clinical ones.

IVIG typically requires traveling to an infusion center or arranging home nursing visits. Sessions last several hours, and many patients feel unwell for 24-48 hours afterward. Work schedules, school, and social plans must accommodate monthly half-day or full-day commitments.

SCIg can be self-administered at home after initial training (usually 2-3 supervised sessions). Patients control their own schedule, can infuse in the evening while watching television, and generally experience no post-infusion “recovery day.” For families with children on immunoglobulin therapy, this flexibility can be transformative.

A Reality Check on Independence

Self-infusion does come with responsibilities that not every patient wants. Managing supplies, maintaining a clean infusion area, rotating injection sites, and troubleshooting pump issues require a level of engagement that some patients find stressful rather than empowering. Patients who feel most comfortable with medical professionals handling their treatment may genuinely prefer the structured environment of an infusion center.

Cost and Insurance Realities

The cost picture is more nuanced than the comparison table suggests. While SCIg’s drug cost per gram is similar to IVIG, the total cost of care differs:

• IVIG costs include the drug itself plus infusion center fees, nursing charges, and facility overhead. Home IVIG still requires a skilled nurse for every infusion.
• SCIg eliminates nursing and facility costs after training is complete. However, the higher dose requirement (137%) means more grams of immunoglobulin are needed annually.

Insurance coverage has improved significantly, but prior authorization is standard for both routes. Some insurers have begun preferring SCIg for certain conditions because of lower total cost of care, while others still default to IVIG. Specialty pharmacies familiar with immunoglobulin therapy can often help navigate these conversations.

Who Should Consider Switching to SCIg

Patients who may benefit from transitioning from IVIG to SCIg include those who:

• Experience significant systemic side effects from IVIG (headaches, fatigue, nausea)
• Have poor venous access or veins that have become difficult to access over time
• Value independence and the ability to infuse at home without nursing support
• Experience pronounced trough effects — feeling unwell in the week before their next IVIG infusion
• Have primary immunodeficiency (the best-established indication for SCIg)
• Have CIDP (Hizentra is FDA-approved for CIDP maintenance)

Who Should NOT Switch to SCIg

SCIg is not appropriate for every patient or every situation:

• Patients needing high-dose immunomodulatory therapy — conditions like Guillain-Barré syndrome or acute autoimmune flares requiring 2 g/kg doses are treated with IVIG, not SCIg
• Patients with severe skin conditions or very limited subcutaneous tissue
• Patients or caregivers unable or unwilling to learn self-administration techniques
• Patients on conditions without SCIg FDA approval — while off-label use exists, insurance coverage may be difficult to obtain
• Patients with thrombocytopenia (ITP) — acute treatment requires the rapid onset of high-dose IVIG

What the Transition Looks Like

For patients ready to move from IVIG to SCIg, the transition process typically follows a structured path:

1. Dose calculation: The physician converts the IVIG dose to the SCIg equivalent (typically multiplying by 1.37) and divides it into weekly portions.
2. Training sessions: Two to three supervised infusions teach patients how to prepare supplies, prime the pump, insert needles, manage flow rates, and handle any issues.
3. First solo infusion: Patients infuse independently at home, with phone support available.
4. Follow-up labs: IgG trough levels are checked after 3-5 months to confirm adequate dosing.

Most patients report feeling confident with the process within 2-4 weeks. The learning curve is real but manageable, and the specialty pharmacy providing supplies typically offers ongoing support.